hVIVO (LON:HVO) Stock Price Down 46.3% – What’s Next?

hVIVO plc (LON:HVO) shares were down 46.3% during trading on Saturday . The company traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). Approximately 83,062,000 shares changed hands during trading, an increase of 2,325% from the average daily volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).

Analysts Set New Price Targets

Separately, Shore Capital reissued a “buy” rating on shares of hVIVO in a research report on Friday.

hVIVO Stock Down 46.3%

The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The stock has a 50-day simple moving average of GBX 16.16 and a 200-day simple moving average of GBX 18.04. The firm has a market capitalization of £61.56 million, a PE ratio of 3.59 and a beta of 0.97.

hVIVO (LON:HVO) last released its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share (EPS) for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. Analysts forecast that hVIVO plc will post 1.5492958 EPS for the current year.

Insiders Place Their Bets

In other hVIVO news, insider Yamin Mo’ Khan sold 3,062,246 shares of the firm’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($700,648.48). Company insiders own 14.03% of the company’s stock.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.